Three mega-checks, three continents, and not a single AI model in sight. Refreshing. If you're just joining: robotics money on this beat has been clustering around the layers that make robots actually usable in factories, not brand-new hardware from scratch. The last marker was microagi's $55 million seed, led by Hummingbird, built around worker-captured factory training data for deployment. So now we're watching whether investors keep funding the software and data stack around the robots. This is Startup Fundraising. Today: a $135M brokerage bet, a billion RMB into robot fingertips, and quick meds in Bengaluru. Not one of them obviously dumb — which makes it worse. Alpaca first. We're staying on Robotics data-layer startups — follow the show and you won't miss what comes next. From Omar Faridi at Crowdfund Insider:
Alpaca, a provider of brokerage infrastructure, has announced a substantial $135 million equity raise. The round was spearheaded by Peak XV, with significant backing from Elefund and participation from new and existing investors including Opera Tech Ventures—the venture arm of BNP Paribas Group—and Unbound. When combined with debt financing, primarily from Payward (parent of the global digital asset platform Kraken) and BMO, the total capital infusion reaches $435 million.
Alpaca's headline is $135 million in equity, led by Peak XV, with big backing from Elefund. But the release wants you to hear $435 million — because once you bolt on debt from Payward and BMO, that's the shinier number. So the actual equity is less than a third of the total capital deployed. Same move we just watched on the Halo structure — debt in the numerator to fatten the headline. Right, and this is the second big equity round in months — they raised a hundred fifty at a one-point-one-five billion valuation back in January. Going back to the well that quickly either means momentum, or a burn rate that needs feeding. Here's what has to be true for this to make sense in two years: tokenized assets have to become an actual market with real settlement volume and custody revenue. Right now that's the bet. The market itself is still aspirational. This one's from TechNode:
Yimu Tech, a Chinese developer of tactile sensing hardware and software for embodied-intelligence systems, has completed a Series E financing round of more than RMB1 billion, bringing its valuation above RMB10 billion. The financing was jointly backed by multiple leading RMB funds, USD funds and industrial investors. The company is developing tactile sensing materials, chips, algorithms and models for robotic applications.
RMB1 billion into robot touch sensors — materials, chips, algorithms, models. This is the unsexy infrastructure layer I keep saying I want funded. Robots that can't feel are just expensive arms. Over RMB10 billion post-money — call it north of one-point-four billion dollars. That's unicorn scale in a subsector that used to raise a fraction of that. But read the syndicate line: 'multiple leading RMB funds, USD funds and industrial investors.' No single lead named. And there it is again. When the price is set by 'multiple leading funds,' nobody actually set the price. Same structural tell we hit on Wonder's round earlier this week — now it's a Chinese robotics deal wearing the same suit. It puts this next to microagi's factory-training-data bet — the sensing side of embodied AI. Capital's going to R&D plus mass production and order delivery, so at least some of this is real lines running, not slideware. The industrial investors are the tell for me. Are they customers writing checks — actual order flow — or just balance-sheet money hedging the embodied-AI theme? That distinction is basically the whole valuation. Shrishti Bisht, writing in Inc42:
Quick medicine delivery startup Plazza has raised $15 Mn (about ₹145 Cr) in a Series A funding round co-led by Accel, Elevation Capital and Nexus Venture Partners. The round also saw participation from existing investors All In Capital and Better Capital. The Bengaluru-based startup plans to use the fresh capital to strengthen its technology platform and deepen its AI-led inventory and assortment capabilities.
Fifteen million into a company that runs two pharmacy stores. Two. Accel, Elevation, and Nexus all co-leading — that's three of the sharpest India funds in one room for a Series A this early. Three top-tier firms on a fifteen-million round. Do the dilution math slowly and that's a crowded cap table before Plazza's even left Bengaluru. Founder's ex-Zomato, so the quick-commerce playbook is in the DNA. But medicine delivery isn't dark-store dosas — the regulatory complexity in India is real, and it isn't solved. So what does the fifteen million actually unlock that a licensing change can't take back? The pitch is 40,000 SKUs per store versus 5,000 at a corner chemist. That's the moat they're selling — assortment plus AI inventory. Whether that justifies three brand-name leads at two stores is the open question. If you track fundraising markets, check out Infrastructure Secondaries Daily. It follows LP stake sales, GP-led continuation vehicles, and discount-to-NAV pricing — useful context on private-market liquidity and pricing signals. Find it wherever you listen to podcasts.
We’ve put links to every story from today’s briefing in the show notes, so if one caught your ear, you can follow it there and read a little deeper. That’s Startup Fundraising for today. This is a Lantern Podcast.